Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional bulk product and the final freeze-dried doses of its mpox and smallpox vaccine, Jynneos, it said on Tuesday.

Bavarian Nordic A/S, one of the only companies with a vaccine approved for mpox, has received regulatory approval in Europe for the use of its jab for adolescents.

Anthem Blue Cross Blue Shield is taking an unusually hard line on doctors who it says improperly prescribed Ozempic.

Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.

Bavarian Nordic’s MVA-BN vaccine is called Imvanex in Europe but is known as Jynneos in countries such as the US and Singapore. Currently, the vaccine is only approved for adults by the US Food and Drug Administration (FDA).

Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as essential for containing an outbreak in parts of Africa, with the World Health Organization declaring mpox a global public health emergency.

The EU's drug regulator has approved Bavarian Nordic's mpox vaccine for use in adolescents aged 12 to 17 years, the company said on Thursday, bolstering evidence for using the shot in that age group to contain an outbreak in parts of Africa.

Bavarian Nordic receives WHO prequalification for IMVANEX as the first vaccine against mpox, accelerating access in African countries.

The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17. "Although the overall risk of being infected with mpox for the general EU population remains low,